Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-Current Deferred Tax Liability (2021 - 2023)

Aytu Biopharma (AYTU) has disclosed Non-Current Deferred Tax Liability for 4 consecutive years, with $100000.0 as the latest value for Q2 2023.

  • Quarterly Non-Current Deferred Tax Liability changed 0.0% to $100000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $100000.0 through Jun 2023, changed 0.0% year-over-year, with the annual reading at $100000.0 for FY2023, 0.0% changed from the prior year.
  • Non-Current Deferred Tax Liability for Q2 2023 was $100000.0 at Aytu Biopharma, roughly flat from $100000.0 in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $200000.0 in Q2 2021, with the low at $100000.0 in Q3 2021.
  • Average Non-Current Deferred Tax Liability over 3 years is $120000.0, with a median of $100000.0 recorded in 2021.
  • The sharpest move saw Non-Current Deferred Tax Liability plummeted 50.0% in 2022, then changed 0.0% in 2023.
  • Over 3 years, Non-Current Deferred Tax Liability stood at $100000.0 in 2021, then changed by 0.0% to $100000.0 in 2022, then changed by 0.0% to $100000.0 in 2023.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $100000.0, $100000.0, and $100000.0 for Q2 2023, Q2 2022, and Q4 2021 respectively.